SUNNYVALE, Calif., Jan. 19 /PRNewswire/ -- Scios Inc. (Nasdaq: SCIO)
announced today that it has filed a shelf Registration Statement with the
Securities and Exchange Commission (SEC), which, upon being declared effective
by the SEC, would allow the Company to issue from time to time up to
$120 million of its common stock. The nature and terms of any offering will
be established at the time of sale. Proceeds of any offering are expected to
be used to fund the Company's new product development and commercialization
activities, including the launch of Natrecor, and other general corporate
purposes.
The Registration Statement relating to these securities has been filed
with the Securities and Exchange Commission but has not yet become effective.
These securities may not be sold nor may offers to buy these securities be
accepted prior to the time the Registration Statement becomes effective. This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy nor shall there be any sale of these securities in any state in
which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.
Scios Inc.
Scios is a biopharmaceutical company developing novel treatments for heart
failure and inflammatory diseases. The company's disease-based technology
platform integrates expertise in protein biology with combinatorial and
medicinal chemistry to identify novel targets and rationally design large and
small-molecule compounds to treat cardiovascular and inflammatory diseases.
Additional information on Scios is available at its web site located at
http://www.sciosinc.com and in the company's various filings with the Securities and
Exchange Commission.
SOURCE Scios Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
Wendy Carhart of Scios Inc., 408-616-8325
|
